fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 14 Blisters
- RxCUI
- 1424899
- RxNorm name
- fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 14 Blisters
- Display name
- fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 14 Blisters
- Full name
- fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 14 Blisters
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:09
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Breo Ellipta | FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE | GlaxoSmithKline LLC | 96428df1-ea05-431a-98d3-1ec2c4b63878 | 2024-11-07 | Warnings, Adverse reactions | 1424899 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 96428df1-ea05-431a-98d3-1ec2c4b63878 | fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 14 Blisters [PSN] · 14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [SCD] | 2 | 28 | These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2013 | 20241107 |